COMBINATION THERPAY COMBINING CAR + T CELLS WITH APPROPRIATELY TIMED IMMUNODULATORY ANTIBODIES
    1.
    发明申请
    COMBINATION THERPAY COMBINING CAR + T CELLS WITH APPROPRIATELY TIMED IMMUNODULATORY ANTIBODIES 审中-公开
    组合使用具有特异性定时免疫抑制抗体的CAR + T细胞的组合

    公开(公告)号:WO2017035117A1

    公开(公告)日:2017-03-02

    申请号:PCT/US2016/048135

    申请日:2016-08-23

    Abstract: In some embodiments, the present disclosure pertains to a method of enhancing chimeric antigen receptor expressing T cell function. In some embodiments, the method comprises activating the chimeric antigen receptor expressing T cells. In some embodiments, the method further comprises determining the differential expression of at least one molecule on the chimeric antigen receptor T cells. In some embodiments, the method comprises targeting the at least one molecule. In some embodiments, the present disclosure pertains to a method of treating a tumor in a subject in need thereof. In some embodiments, the method comprises administering to the subject an infusion of chimeric antigen receptor expressing T cells. In some embodiments, the method further comprises determining the differential expression of at least one molecule on the chimeric antigen receptor T cells. In some embodiments, the method comprises targeting the at least one molecule, wherein the molecule is differentially expressed upon activation of the chimeric antigen receptor expressing T cells.

    Abstract translation: 在一些实施方案中,本公开涉及增强表达T细胞功能的嵌合抗原受体的方法。 在一些实施方案中,该方法包括激活表达T嵌合抗原的T细胞。 在一些实施方案中,所述方法还包括测定嵌合抗原受体T细胞上至少一个分子的差异表达。 在一些实施方案中,该方法包括靶向至少一种分子。 在一些实施方案中,本公开涉及在有需要的受试者中治疗肿瘤的方法。 在一些实施方案中,所述方法包括向受试者施用表达T细胞的嵌合抗原受体的输注。 在一些实施方案中,所述方法还包括测定嵌合抗原受体T细胞上至少一个分子的差异表达。 在一些实施方案中,所述方法包括靶向所述至少一种分子,其中所述分子在表达T细胞的嵌合抗原受体活化时被差异表达。

Patent Agency Ranking